Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are evaluating Izalontamab Brengitecan compared to platinum-based chemotherapy for patients with metastatic urothelial cancer that has progressed after immunotherapy. This Phase 23 randomized trial aims to find the best dose and assess progression-free survival and overall survival over up to five years. Participants must have confirmed advanced urothelial carcinoma and have experience with Anti-PD-L1 therapy. Participants will be assigned to receive either Izalontamab Brengitecan or platinum-based chemotherapy such as Cisplatin, Gemcitabine, or Carboplatin at specified doses on defined days. The study includes several arms and evaluates treatment effects in parallel groups. The Phase 2 portion focuses on determining the recommended Phase 3 dose, while Phase 3 assesses efficacy outcomes over several years. Throughout the trial, participants will undergo regular assessments including tumor measurement by RECIST v1.1, performance status evaluations, antibody-drug conjugate concentrations, and quality of life measurements. Outcome measures include progression-free survival, overall survival, objective response, duration of response, and time to response. The study involves long-term follow-up lasting up to five years to monitor treatment effects and safety.
Actively Recruiting
Researchers are evaluating treatments for prostate cancer patients who have experienced a return of cancer markers biochemical recurrence after prostate surgery. This phase III trial compares whether adding enhanced therapy apalutamide with abiraterone and prednisone to standard care radiation therapy and short-term hormone therapy improves outcomes for patients without signs of cancer spread outside the pelvis. For patients with evidence of cancer spread beyond the pelvis detected by PET imaging, the study also tests whether adding targeted radiation to enhanced therapy provides additional benefit. Participants undergo baseline PET scans to identify the presence or absence of cancer spread outside the pelvis. Based on these results, they are randomly assigned to one of four treatment groups involving combinations of standard external radiation therapy, androgen deprivation therapies such as goserelin, leuprolide, triptorelin, relugolix, or degarelix, apalutamide taken daily by mouth, and for some, additional targeted radiation to metastatic sites. Treatments generally continue for six months unless disease progression or side effects occur. Patients may undergo additional PET imaging during the study to monitor response. Throughout the trial, participants will have regular follow-up visits every three months for two years, then every six months for years three to five, and annually up to ten years. Assessments include imaging scans, blood tests for prostate-specific antigen PSA, and quality-of-life evaluations using standardized questionnaires focusing on fatigue, pain, and cognitive function. Researchers will measure progression-free survival, overall survival, incidence of side effects, and quality of life up to ten years after treatment begins.